GPX2 can also directly inhibit the NF-κB pathway, which plays a key role in innate immune activation and whose dysregulation contributes to the pathogenesis of various inflammatory diseases, including IBD [207,208]. Here, NFKB1 is linked to irritable bowel syndrome.